People · Operator
Named in public records as an officer, director or promoter · active 2009–2026 · Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Altesa BioSciences, Inc. | — | Pharmaceuticals | Series C | $110.0M | $373.5M | 2022 |
| Vaxinnate Corp | — | Biotechnology | Series B | $92.6M | $128.9M | 2009 |
| Liquidia Technologies Inc | — | Biotechnology | Series B | $86.7M | $890.0M | 2009 |
| Envisia Therapeutics, Inc. | — | Biotechnology | Series A | $14.7M | $365.8M | 2015 |
| LQ3 Pharmaceuticals, Inc. | — | Pharmaceuticals | Seed | $4.4M | $89.5M | 2014 |
Seth Rudnick at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Seth Rudnick on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Stephen Bloch | 3 | 15 |
| Neal Fowler | 3 | 4 |
| Ed Mathers | 2 | 11 |
| David Williams | 1 | 17 |
| Isaac Cheng | 1 | 9 |
| Augustine Lawlor | 1 | 8 |
| Adrienne Graves | 1 | 6 |
| Ittai Harel | 1 | 6 |
| Joseph DeSimone | 1 | 5 |
| Eric Linsley | 1 | 4 |
| Ralph Snyderman | 1 | 4 |
| Gary Phillips | 1 | 4 |
| Steve Nelson | 1 | 4 |
| Julie Eskay-Eagle | 1 | 3 |
| Moncef Slaoui | 1 | 3 |
| Brett Giroir | 1 | 3 |
| Seth A. Rudnick | 1 | 3 |
| Ralph S. Snyderman | 1 | 2 |
| William Yelle | 1 | 2 |
| Augustine O. Lawlor | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.